MIMEDX GROUP INC (MDXG)
US6024961012 - Common Stock
Taking everything into account, MDXG scores 6 out of 10 in our fundamental rating. MDXG was compared to 588 industry peers in the Biotechnology industry. MDXG has an excellent financial health rating, but there are some minor concerns on its profitability. MDXG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
In the past year MDXG had a positive cash flow from operations.
MDXG had negative earnings in 4 of the past 5 years.
MDXG had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of MDXG (23.34%) is better than 99.49% of its industry peers.
MDXG has a Return On Equity of 39.09%. This is amongst the best in the industry. MDXG outperforms 98.97% of its industry peers.
MDXG has a better Return On Invested Capital (17.31%) than 98.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.34% | ||
| ROE | 39.09% | ||
| ROIC | 17.31% |
ROA(3y)-2.29%
ROA(5y)-12.68%
ROE(3y)-9.34%
ROE(5y)-38.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG has a Profit Margin of 17.35%. This is amongst the best in the industry. MDXG outperforms 97.26% of its industry peers.
MDXG has a better Operating Margin (13.15%) than 95.89% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 83.00%, MDXG belongs to the top of the industry, outperforming 88.36% of the companies in the same industry.
MDXG's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.15% | ||
| PM (TTM) | 17.35% | ||
| GM | 83% |
OM growth 3Y29.31%
OM growth 5Y-0.07%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.46%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MDXG is creating value.
Compared to 1 year ago, MDXG has more shares outstanding
MDXG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, MDXG has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 7.46 indicates that MDXG is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.46, MDXG belongs to the top of the industry, outperforming 85.10% of the companies in the same industry.
MDXG has a debt to FCF ratio of 1.99. This is a very positive value and a sign of high solvency as it would only need 1.99 years to pay back of all of its debts.
MDXG has a better Debt to FCF ratio (1.99) than 95.72% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that MDXG is not too dependend on debt financing.
MDXG's Debt to Equity ratio of 0.34 is on the low side compared to the rest of the industry. MDXG is outperformed by 71.06% of its industry peers.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 7.46 |
ROIC/WACC1.85
WACC9.36%
2.3 Liquidity
MDXG has a Current Ratio of 3.57. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio (3.57) which is comparable to the rest of the industry.
MDXG has a Quick Ratio of 3.11. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a worse Quick ratio (3.11) than 64.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.11 |
3. Growth
3.1 Past
MDXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 196.97%, which is quite impressive.
MDXG shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.03%.
Measured over the past years, MDXG shows a decrease in Revenue. The Revenue has been decreasing by -2.19% on average per year.
EPS 1Y (TTM)196.97%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q1700%
Revenue 1Y (TTM)20.03%
Revenue growth 3Y9.01%
Revenue growth 5Y-2.19%
Revenue growth Q2Q16.74%
3.2 Future
The Earnings Per Share is expected to grow by 38.07% on average over the next years. This is a very strong growth
Based on estimates for the next years, MDXG will show a quite strong growth in Revenue. The Revenue will grow by 11.55% on average per year.
EPS Next Y-1.82%
EPS Next 2Y11.5%
EPS Next 3Y18.72%
EPS Next 5Y38.07%
Revenue Next Year11.67%
Revenue Next 2Y12.31%
Revenue Next 3Y12.2%
Revenue Next 5Y11.55%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.59, MDXG is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 96.40% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of MDXG to the average of the S&P500 Index (24.92), we can say MDXG is valued slightly cheaper.
With a Price/Forward Earnings ratio of 19.96, MDXG is valued on the expensive side.
Based on the Price/Forward Earnings ratio, MDXG is valued cheaper than 96.58% of the companies in the same industry.
MDXG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.49.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.59 | ||
| Fwd PE | 19.96 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 95.72% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 95.55% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.43 | ||
| EV/EBITDA | 19.36 |
4.3 Compensation for Growth
The decent profitability rating of MDXG may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 18.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.5%
EPS Next 3Y18.72%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIMEDX GROUP INC
NASDAQ:MDXG (4/26/2024, 7:03:04 PM)
6.27
+0.02 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap921.44M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.59 | ||
| Fwd PE | 19.96 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.34% | ||
| ROE | 39.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.15% | ||
| PM (TTM) | 17.35% | ||
| GM | 83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.34 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)196.97%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.03%
Revenue growth 3Y9.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y